202 related articles for article (PubMed ID: 35190109)
1. Immunotherapy-Related Acute Kidney Injury.
Manohar S; Jhaveri KD; Perazella MA
Adv Chronic Kidney Dis; 2021 Sep; 28(5):429-437.e1. PubMed ID: 35190109
[TBL] [Abstract][Full Text] [Related]
2. Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future.
Perazella MA; Shirali AC
J Am Soc Nephrol; 2018 Aug; 29(8):2039-2052. PubMed ID: 29959196
[TBL] [Abstract][Full Text] [Related]
3. Acute Kidney Injury in Cancer Immunotherapy Recipients.
Joseph A; Lafarge A; Azoulay E; Zafrani L
Cells; 2022 Dec; 11(24):. PubMed ID: 36552755
[TBL] [Abstract][Full Text] [Related]
4. The nephrotoxicity of new immunotherapies.
Sury K; Perazella MA
Expert Rev Clin Pharmacol; 2019 Jun; 12(6):513-521. PubMed ID: 31035801
[No Abstract] [Full Text] [Related]
5. Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer.
Rahman MM; Behl T; Islam MR; Alam MN; Islam MM; Albarrati A; Albratty M; Meraya AM; Bungau SG
Molecules; 2022 Jun; 27(12):. PubMed ID: 35744922
[TBL] [Abstract][Full Text] [Related]
6. A review of cancer immunotherapy toxicity.
Kennedy LB; Salama AKS
CA Cancer J Clin; 2020 Mar; 70(2):86-104. PubMed ID: 31944278
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer.
Ragoonanan D; Khazal SJ; Abdel-Azim H; McCall D; Cuglievan B; Tambaro FP; Ahmad AH; Rowan CM; Gutierrez C; Schadler K; Li S; Di Nardo M; Chi L; Gulbis AM; Shoberu B; Mireles ME; McArthur J; Kapoor N; Miller J; Fitzgerald JC; Tewari P; Petropoulos D; Gill JB; Duncan CN; Lehmann LE; Hingorani S; Angelo JR; Swinford RD; Steiner ME; Hernandez Tejada FN; Martin PL; Auletta J; Choi SW; Bajwa R; Dailey Garnes N; Kebriaei P; Rezvani K; Wierda WG; Neelapu SS; Shpall EJ; Corbacioglu S; Mahadeo KM
Nat Rev Clin Oncol; 2021 Jul; 18(7):435-453. PubMed ID: 33608690
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors.
Cortazar FB; Marrone KA; Troxell ML; Ralto KM; Hoenig MP; Brahmer JR; Le DT; Lipson EJ; Glezerman IG; Wolchok J; Cornell LD; Feldman P; Stokes MB; Zapata SA; Hodi FS; Ott PA; Yamashita M; Leaf DE
Kidney Int; 2016 Sep; 90(3):638-47. PubMed ID: 27282937
[TBL] [Abstract][Full Text] [Related]
9. Onconephrology: mitigation of renal injury in chemotherapy administration.
Selamet U; Ahdoot RS; Salasnek R; Abdelnour L; Hanna RM
Curr Opin Nephrol Hypertens; 2024 Mar; 33(2):257-266. PubMed ID: 38095483
[TBL] [Abstract][Full Text] [Related]
10. Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.
Thompson JA; Schneider BJ; Brahmer J; Achufusi A; Armand P; Berkenstock MK; Bhatia S; Budde LE; Chokshi S; Davies M; Elshoury A; Gesthalter Y; Hegde A; Jain M; Kaffenberger BH; Lechner MG; Li T; Marr A; McGettigan S; McPherson J; Medina T; Mohindra NA; Olszanski AJ; Oluwole O; Patel SP; Patil P; Reddy S; Ryder M; Santomasso B; Shofer S; Sosman JA; Wang Y; Zaha VG; Lyons M; Dwyer M; Hang L
J Natl Compr Canc Netw; 2022 Apr; 20(4):387-405. PubMed ID: 35390769
[TBL] [Abstract][Full Text] [Related]
11. Immune-related adverse events of checkpoint inhibitors: Insights into immunological dysregulation.
Yang H; Yao Z; Zhou X; Zhang W; Zhang X; Zhang F
Clin Immunol; 2020 Apr; 213():108377. PubMed ID: 32135278
[TBL] [Abstract][Full Text] [Related]
12. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.
Martins F; Sofiya L; Sykiotis GP; Lamine F; Maillard M; Fraga M; Shabafrouz K; Ribi C; Cairoli A; Guex-Crosier Y; Kuntzer T; Michielin O; Peters S; Coukos G; Spertini F; Thompson JA; Obeid M
Nat Rev Clin Oncol; 2019 Sep; 16(9):563-580. PubMed ID: 31092901
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy-Associated Cardiotoxicity of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T Cell Therapy: Diagnostic and Management Challenges and Strategies.
Stein-Merlob AF; Rothberg MV; Holman P; Yang EH
Curr Cardiol Rep; 2021 Jan; 23(3):11. PubMed ID: 33483873
[TBL] [Abstract][Full Text] [Related]
14. Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review.
Wanchoo R; Karam S; Uppal NN; Barta VS; Deray G; Devoe C; Launay-Vacher V; Jhaveri KD;
Am J Nephrol; 2017; 45(2):160-169. PubMed ID: 28076863
[TBL] [Abstract][Full Text] [Related]
15. Neurologic Toxicities of Cancer Immunotherapies: a Review.
Harrison RA; Tummala S; de Groot J
Curr Neurol Neurosci Rep; 2020 Jun; 20(7):27. PubMed ID: 32514633
[TBL] [Abstract][Full Text] [Related]
16. Toxicities Associated with Immunotherapy and Approach to Cardiotoxicity with Novel Cancer Therapies.
Gutierrez C; Rajendram P; Pastores SM
Crit Care Clin; 2021 Jan; 37(1):47-67. PubMed ID: 33190775
[TBL] [Abstract][Full Text] [Related]
17. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
Madden DL
Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers.
Inthagard J; Edwards J; Roseweir AK
Clin Sci (Lond); 2019 Jan; 133(2):181-193. PubMed ID: 30659159
[TBL] [Abstract][Full Text] [Related]
19. Inflammatory and Infectious Syndromes Associated With Cancer Immunotherapies.
Fishman JA; Hogan JI; Maus MV
Clin Infect Dis; 2019 Aug; 69(6):909-920. PubMed ID: 30520987
[TBL] [Abstract][Full Text] [Related]
20. Upcoming innovations in lung cancer immunotherapy: focus on immune checkpoint inhibitors.
Aspeslagh S; Marabelle A; Soria JC; Armand JP
Chin Clin Oncol; 2015 Dec; 4(4):48. PubMed ID: 26730760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]